OBJECTIVE: To investigate the efficacy of oral prednisolone in virally induced respiratory distress. Study design Randomized, double-blind, placebo-controlled trial involving 230 children age 6 to 35 months in the emergency department. Each patient received either oral prednisolone (2 mg/kg/d) or placebo for 3 days. RESULTS: The hospitalization rates were similar between the two groups. For admitted children (n=123), the median length of stay was 1 day shorter in the prednisolone group (2 vs 3 days, P=.060). The proportion of children requiring >or=3 days of hospitalization was 47.5% in the prednisolone group and 67.7% in the placebo group (P=.023). There was less need for additional asthma medication (18.0% vs 37.1%, P=.018) in the prednisolone group. The median duration of symptoms of respiratory distress was 1 day in the prednisolone group versus 2 days in the placebo group both among the hospitalized (P<.001) and nonhospitalized children (P=.006). CONCLUSION: A 3-day course of oral prednisolone effectively reduced disease severity, length of hospital stay, and the duration of symptoms among children 6 to 35 months old with virally induced respiratory distress.
RCT Entities:
OBJECTIVE: To investigate the efficacy of oral prednisolone in virally induced respiratory distress. Study design Randomized, double-blind, placebo-controlled trial involving 230 children age 6 to 35 months in the emergency department. Each patient received either oral prednisolone (2 mg/kg/d) or placebo for 3 days. RESULTS: The hospitalization rates were similar between the two groups. For admitted children (n=123), the median length of stay was 1 day shorter in the prednisolone group (2 vs 3 days, P=.060). The proportion of children requiring >or=3 days of hospitalization was 47.5% in the prednisolone group and 67.7% in the placebo group (P=.023). There was less need for additional asthma medication (18.0% vs 37.1%, P=.018) in the prednisolone group. The median duration of symptoms of respiratory distress was 1 day in the prednisolone group versus 2 days in the placebo group both among the hospitalized (P<.001) and nonhospitalized children (P=.006). CONCLUSION: A 3-day course of oral prednisolone effectively reduced disease severity, length of hospital stay, and the duration of symptoms among children 6 to 35 months old with virally induced respiratory distress.
Authors: Manfred Götz; Ernst Eber; Thomas Frischer; Elisabeth Horak; Herbert Kurz; Josef Riedler; Rudolf Schmitzberger; Maximilian Zach Journal: Wien Klin Wochenschr Date: 2006-05 Impact factor: 1.704
Authors: Avraham Beigelman; Tonya S King; David Mauger; Robert S Zeiger; Robert C Strunk; H William Kelly; Fernando D Martinez; Robert F Lemanske; Katherine Rivera-Spoljaric; Daniel J Jackson; Theresa Guilbert; Ronina Covar; Leonard B Bacharier Journal: J Allergy Clin Immunol Date: 2013-03-14 Impact factor: 10.793
Authors: Ricardo M Fernandes; Liza M Bialy; Ben Vandermeer; Lisa Tjosvold; Amy C Plint; Hema Patel; David W Johnson; Terry P Klassen; Lisa Hartling Journal: Cochrane Database Syst Rev Date: 2013-06-04